Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
REVELATION BIOSCIENCES INC (REVB)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$4.12-7.05%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for REVB yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Improve cash flow from operations from negative $3.21 million | The company aims to improve financial stability by addressing negative operating income near $3.1 million and negative cash flow around $3.2 million. | Broken | cash flow from operations worsens beyond negative $3.2 million next 4 quarters | Cash from operations: $-2.557M FY2026-Q2; GAAP. Published target: Cash flow from operations improves to better than negative $3 million. Target period is not explicitly aligned with this observation. Aug 6, 2026-2,557,193 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 5, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative clinical-stage company, not an established earnings compounder. The thesis is in a watch state: management is advancing its lead study and managing cash, but confidence in the evidence is low and business risk is high.
The snapshot provides no valuation measure or direct evidence about what the market expects, so whether REVB is cheap or expensive versus peers cannot be assessed. Recent performance is well below its industry cohort, and the thesis already reflects a recent earnings miss and a run of misses.
Near term, earnings execution looks weak, with elevated risk of another miss. Over the multi-year view, progress depends on advancing the Gemini pivotal study for acute kidney injury; management says enrollment is planned by year-end 2026, and start-up work remains on track. Cash rose modestly through 2026-Q2, but operating cash use was about $2.6M to $3.2M per quarter, and management projects funding through Q1 2027.
A guidance cut or further weakening in the jobs report could add pressure to the business outlook, while stronger results and guidance from healthcare peers could support sector momentum. The central company-specific test is whether Gemini enrollment begins on schedule and cash remains sufficient to sustain operations beyond the stated runway.
For the next 1 to 3 years, REVB is a fragile clinical-stage thesis with credible study and cash-management priorities, but weak recent performance, repeated misses, and limited runway keep uncertainty high. The evidence snapshot offers little basis to assess valuation expectations. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stable leadership after CEO and CFO agreement amendments | A supporting condition in REVELATION BIOSCIENCES INC's published investment case. The stated target is No further disruptive leadership changes in next 4 quarters. | Intact | Unexpected CEO or CFO departure within next 4 quarters | No disruptive leadership changes reported Recent filings show restricted stock awards and amended employment agreements for CEO/CFO, confirming continued tenure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Reduce operating losses from negative $3.09 million | The company aims to improve financial stability by addressing negative operating income near $3.1 million and negative cash flow around $3.2 million. | Broken | operating loss worsens beyond negative $3.1 million next 4 quarters | Operating income: $-3.662M FY2026-Q2; GAAP. Published target: Operating loss improves to better than negative $3 million. Target period is not explicitly aligned with this observation. Aug 6, 2026-3,662,241 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-2.77 → $-20.23 · observed estimates
$0.00B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-2.77 | $2,284,000 | 2 / 2 |
| 2026-07-25 | $-2.77 | $2,284,000 | 2 / 2 |
| 2026-07-26 | $-2.77 | $0 | 2 / 2 |
| 2026-07-27 | $-2.77 | $0 | 2 / 2 |
| 2026-07-28 | $-2.77 | $0 | 2 / 2 |
| 2026-07-29 | $-2.77 | $0 | 2 / 2 |
| 2026-07-30 | $-2.77 | $0 | 2 / 2 |
| 2026-07-31 | $-2.77 | $2,284,000 | 2 / 2 |
| 2026-08-01 | $-2.77 | $2,284,000 | 2 / 2 |
| 2026-08-02 | $-2.77 | $0 | 2 / 2 |
| 2026-08-03 | $-2.77 | $2,284,000 | 2 / 2 |
| 2026-08-04 | $-2.77 | $2,284,000 | 2 / 2 |
| 2026-08-05 | $-2.77 | $0 | 2 / 2 |
| 2026-08-06 | $-2.77 | $0 | 2 / 2 |
| 2026-08-08 | $-2.77 | $0 | 2 / 2 |
| 2026-08-09 | $-2.99 | $0 | 2 / 2 |
| 2026-08-10 | $-2.99 | $0 | 2 / 2 |
| 2026-08-12 | $-2.99 | $0 | 2 / 2 |
| 2026-08-13 | $-2.77 | $2,284,000 | 2 / 2 |
| 2026-08-14 | $-2.77 | $2,284,000 | 2 / 2 |
| 2026-08-15 | $-2.77 | $2,284,000 | 2 / 2 |
| 2026-08-16 | $-2.77 | $2,284,000 | 2 / 2 |
| 2026-08-17 | $-2.77 | $2,284,000 | 2 / 2 |
| 2026-08-18 | $-2.77 | $2,284,000 | 2 / 2 |
| 2026-08-19 | $-2.77 | $2,284,000 | 2 / 2 |
| 2026-08-20 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-08-21 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-08-22 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-08-23 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-08-24 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-08-25 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-08-26 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-08-27 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-08-28 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-08-29 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-08-30 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-08-31 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-09-01 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-09-02 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-09-03 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-09-04 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-09-05 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-09-06 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-09-07 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-09-08 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-09-09 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-09-10 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-09-11 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-09-12 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-09-13 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-09-14 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-09-15 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-09-16 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-09-17 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-09-18 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-09-19 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-09-20 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-09-21 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-09-22 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-09-23 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-09-24 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-09-25 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-09-26 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-09-27 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-09-28 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-09-29 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-09-30 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-10-01 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-10-02 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-10-03 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-10-04 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-10-05 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-10-06 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-10-07 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-10-08 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-10-09 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-10-10 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-10-11 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-10-12 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-10-13 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-10-14 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-10-15 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-10-16 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-10-17 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-10-18 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-10-19 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-10-20 | $-2.89 | $2,284,000 | 2 / 2 |
| 2026-10-21 | $-20.23 | $2,284,000 | 2 / 2 |
| 2026-10-22 | $-20.23 | $2,284,000 | 2 / 2 |
| 2026-10-23 | $-20.23 | $2,284,000 | 2 / 2 |
| 2026-10-24 | $-20.23 | $2,284,000 | 2 / 2 |
| 2026-10-25 | $-20.23 | $2,284,000 | 2 / 2 |
| 2026-10-26 | $-20.23 | $2,284,000 | 2 / 2 |
| 2026-10-27 | $-20.23 | $2,284,000 | 2 / 2 |
| 2026-10-28 | $-20.23 | $2,284,000 | 2 / 2 |
| 2026-10-29 | $-20.23 | $2,284,000 | 2 / 2 |
| 2026-10-30 | $-20.23 | $2,284,000 | 2 / 2 |
| 2026-10-31 | $-20.23 | $2,284,000 | 2 / 2 |
| 2026-11-01 | $-20.23 | $2,284,000 | 2 / 2 |
| 2026-11-02 | $-20.23 | $2,284,000 | 2 / 2 |
| 2026-11-03 | $-20.23 | $2,284,000 | 2 / 2 |
| 2026-11-04 | $-20.23 | $2,284,000 | 2 / 2 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 1 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.